Peracetylation as a means of enhancing in vitro bioactivity and bioavailability of epigallocatechin-3-gallate

Joshua D. Lambert, Shengmin Sang, Jungil Hong, Seok Joo Kwon, Mao Jung Lee, Chi Tang Ho, Chung S. Yang

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

(-)-Epigallocatechin-3-gallate (EGCG) is the widely studied catechin in green tea (Camellia sinensis). Previously, we have reported the low bioavailability of EGCG in rats and mice. As a means of improving the bioavailability of EGCG, we have prepared a peracetylated EGCG derivative (AcEGCG) and herein report its growth inhibitory activity and cellular uptake in vitro, as well as bioavailability in mice. AcEGCG exhibited enhanced growth inhibitory activity relative to EGCG in both KYSE150 human esophageal (IC 50 = 10 versus 20 μM) and HCT116 human colon cancer cells (IC 50 = 32 versus 45 μM). AcEGCG was rapidly converted to EGCG by HCT116 cells, and treatment of cells with AcEGCG resulted in a 2.8- to 30-fold greater intracellular concentration of EGCG as compared with treatment with EGCG. AcEGCG was also more potent than EGCG at inhibiting nitric oxide production (4.4-fold) and arachidonic acid release (2.0-fold) from lipopolysaccharide-stimulated RAW264.7 murine macrophages. Intragastric administration of AcEGCG to CF-1 mice resulted in higher bioavailability compared with administration of equimolar doses of EGCG. The plasma area under the curve from 0 to infinity (AUC0→∞) of total EGCG was 465.0 and 194.6 [(μg/ml)·min] from the administration of AcEGCG and EGCG, respectively. The t1/2 of EGCG was also increased following administration of AcEGCG compared with EGCG (441.0 versus 200.3 min). The AUC0→∞ and t1/2 were also increased in small intestinal (2.8- and 4.3-fold, respectively) and colonic tissues (2.4- and 6.0-fold, respectively). These data suggest that acetylation represents a means of increasing the biological potency in vitro, increasing the bioavailability of EGCG in vivo, and may improve cancer-preventive activity.

Original languageEnglish (US)
Pages (from-to)2111-2116
Number of pages6
JournalDrug Metabolism and Disposition
Volume34
Issue number12
DOIs
StatePublished - Dec 1 2006

Fingerprint

Biological Availability
In Vitro Techniques
epigallocatechin gallate
Camellia sinensis
HCT116 Cells
Catechin
Tea
Acetylation
Growth
Arachidonic Acid
Colonic Neoplasms
Area Under Curve
Lipopolysaccharides
Nitric Oxide
Macrophages

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science

Cite this

Lambert, Joshua D. ; Sang, Shengmin ; Hong, Jungil ; Kwon, Seok Joo ; Lee, Mao Jung ; Ho, Chi Tang ; Yang, Chung S. / Peracetylation as a means of enhancing in vitro bioactivity and bioavailability of epigallocatechin-3-gallate. In: Drug Metabolism and Disposition. 2006 ; Vol. 34, No. 12. pp. 2111-2116.
@article{8a511d40eed943019b677652a644359b,
title = "Peracetylation as a means of enhancing in vitro bioactivity and bioavailability of epigallocatechin-3-gallate",
abstract = "(-)-Epigallocatechin-3-gallate (EGCG) is the widely studied catechin in green tea (Camellia sinensis). Previously, we have reported the low bioavailability of EGCG in rats and mice. As a means of improving the bioavailability of EGCG, we have prepared a peracetylated EGCG derivative (AcEGCG) and herein report its growth inhibitory activity and cellular uptake in vitro, as well as bioavailability in mice. AcEGCG exhibited enhanced growth inhibitory activity relative to EGCG in both KYSE150 human esophageal (IC 50 = 10 versus 20 μM) and HCT116 human colon cancer cells (IC 50 = 32 versus 45 μM). AcEGCG was rapidly converted to EGCG by HCT116 cells, and treatment of cells with AcEGCG resulted in a 2.8- to 30-fold greater intracellular concentration of EGCG as compared with treatment with EGCG. AcEGCG was also more potent than EGCG at inhibiting nitric oxide production (4.4-fold) and arachidonic acid release (2.0-fold) from lipopolysaccharide-stimulated RAW264.7 murine macrophages. Intragastric administration of AcEGCG to CF-1 mice resulted in higher bioavailability compared with administration of equimolar doses of EGCG. The plasma area under the curve from 0 to infinity (AUC0→∞) of total EGCG was 465.0 and 194.6 [(μg/ml)·min] from the administration of AcEGCG and EGCG, respectively. The t1/2 of EGCG was also increased following administration of AcEGCG compared with EGCG (441.0 versus 200.3 min). The AUC0→∞ and t1/2 were also increased in small intestinal (2.8- and 4.3-fold, respectively) and colonic tissues (2.4- and 6.0-fold, respectively). These data suggest that acetylation represents a means of increasing the biological potency in vitro, increasing the bioavailability of EGCG in vivo, and may improve cancer-preventive activity.",
author = "Lambert, {Joshua D.} and Shengmin Sang and Jungil Hong and Kwon, {Seok Joo} and Lee, {Mao Jung} and Ho, {Chi Tang} and Yang, {Chung S.}",
year = "2006",
month = "12",
day = "1",
doi = "10.1124/dmd.106.011460",
language = "English (US)",
volume = "34",
pages = "2111--2116",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "12",

}

Peracetylation as a means of enhancing in vitro bioactivity and bioavailability of epigallocatechin-3-gallate. / Lambert, Joshua D.; Sang, Shengmin; Hong, Jungil; Kwon, Seok Joo; Lee, Mao Jung; Ho, Chi Tang; Yang, Chung S.

In: Drug Metabolism and Disposition, Vol. 34, No. 12, 01.12.2006, p. 2111-2116.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Peracetylation as a means of enhancing in vitro bioactivity and bioavailability of epigallocatechin-3-gallate

AU - Lambert, Joshua D.

AU - Sang, Shengmin

AU - Hong, Jungil

AU - Kwon, Seok Joo

AU - Lee, Mao Jung

AU - Ho, Chi Tang

AU - Yang, Chung S.

PY - 2006/12/1

Y1 - 2006/12/1

N2 - (-)-Epigallocatechin-3-gallate (EGCG) is the widely studied catechin in green tea (Camellia sinensis). Previously, we have reported the low bioavailability of EGCG in rats and mice. As a means of improving the bioavailability of EGCG, we have prepared a peracetylated EGCG derivative (AcEGCG) and herein report its growth inhibitory activity and cellular uptake in vitro, as well as bioavailability in mice. AcEGCG exhibited enhanced growth inhibitory activity relative to EGCG in both KYSE150 human esophageal (IC 50 = 10 versus 20 μM) and HCT116 human colon cancer cells (IC 50 = 32 versus 45 μM). AcEGCG was rapidly converted to EGCG by HCT116 cells, and treatment of cells with AcEGCG resulted in a 2.8- to 30-fold greater intracellular concentration of EGCG as compared with treatment with EGCG. AcEGCG was also more potent than EGCG at inhibiting nitric oxide production (4.4-fold) and arachidonic acid release (2.0-fold) from lipopolysaccharide-stimulated RAW264.7 murine macrophages. Intragastric administration of AcEGCG to CF-1 mice resulted in higher bioavailability compared with administration of equimolar doses of EGCG. The plasma area under the curve from 0 to infinity (AUC0→∞) of total EGCG was 465.0 and 194.6 [(μg/ml)·min] from the administration of AcEGCG and EGCG, respectively. The t1/2 of EGCG was also increased following administration of AcEGCG compared with EGCG (441.0 versus 200.3 min). The AUC0→∞ and t1/2 were also increased in small intestinal (2.8- and 4.3-fold, respectively) and colonic tissues (2.4- and 6.0-fold, respectively). These data suggest that acetylation represents a means of increasing the biological potency in vitro, increasing the bioavailability of EGCG in vivo, and may improve cancer-preventive activity.

AB - (-)-Epigallocatechin-3-gallate (EGCG) is the widely studied catechin in green tea (Camellia sinensis). Previously, we have reported the low bioavailability of EGCG in rats and mice. As a means of improving the bioavailability of EGCG, we have prepared a peracetylated EGCG derivative (AcEGCG) and herein report its growth inhibitory activity and cellular uptake in vitro, as well as bioavailability in mice. AcEGCG exhibited enhanced growth inhibitory activity relative to EGCG in both KYSE150 human esophageal (IC 50 = 10 versus 20 μM) and HCT116 human colon cancer cells (IC 50 = 32 versus 45 μM). AcEGCG was rapidly converted to EGCG by HCT116 cells, and treatment of cells with AcEGCG resulted in a 2.8- to 30-fold greater intracellular concentration of EGCG as compared with treatment with EGCG. AcEGCG was also more potent than EGCG at inhibiting nitric oxide production (4.4-fold) and arachidonic acid release (2.0-fold) from lipopolysaccharide-stimulated RAW264.7 murine macrophages. Intragastric administration of AcEGCG to CF-1 mice resulted in higher bioavailability compared with administration of equimolar doses of EGCG. The plasma area under the curve from 0 to infinity (AUC0→∞) of total EGCG was 465.0 and 194.6 [(μg/ml)·min] from the administration of AcEGCG and EGCG, respectively. The t1/2 of EGCG was also increased following administration of AcEGCG compared with EGCG (441.0 versus 200.3 min). The AUC0→∞ and t1/2 were also increased in small intestinal (2.8- and 4.3-fold, respectively) and colonic tissues (2.4- and 6.0-fold, respectively). These data suggest that acetylation represents a means of increasing the biological potency in vitro, increasing the bioavailability of EGCG in vivo, and may improve cancer-preventive activity.

UR - http://www.scopus.com/inward/record.url?scp=33751517433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751517433&partnerID=8YFLogxK

U2 - 10.1124/dmd.106.011460

DO - 10.1124/dmd.106.011460

M3 - Article

VL - 34

SP - 2111

EP - 2116

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 12

ER -